Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + adebrelimab + mirabegron
- Development stage
- Unknown
- Lead developer
- Obstetrics and Gynecology Hospital of Fudan University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is a multi-modal regimen consisting of the cytotoxic chemotherapy pegylated liposomal doxorubicin (PLD), the PD-L1 inhibitor adebrelimab, and the beta-3 adrenergic receptor agonist mirabegron. It is currently being evaluated in a Phase 2/3 clinical trial by the Obstetrics & Gynecology Hospital of Fudan University for the treatment of relapsed ovarian cancer. Pegylated liposomal doxorubicin works by intercalating DNA and inhibiting topoisomerase II, while its liposomal formulation reduces cardiotoxicity and improves pharmacokinetics. Adebrelimab (SHR-1316) is a humanized monoclonal antibody that blocks the interaction between PD-1 and PD-L1, thereby enhancing the immune system's ability to target tumor cells. Mirabegron, traditionally used for overactive bladder, is included in this regimen to potentially modulate the tumor microenvironment and enhance the efficacy of the chemo-immunotherapy combination.
- Brand names
- DoxilAiruikaMyrbetriqBetmiga
- Other names
- PLD + adebrelimab + mirabegronpegylated liposomal doxorubicin plus adebrelimab with mirabegron
02
Targets
TOP2A (DNA topoisomerase II)ADRB3 (β3)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + adebrelimab + mirabegron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + adebrelimab + mirabegron.